DPK guidance to be withdrawn
FDA will withdraw draft guidance on dermatopharmacokinetics. "We are going to focus on a variety of other methods that make it possible for bioequivalence" for topical dermatologic products, Office of Pharmaceutical Science Acting Director Helen Winkle told the Generic Pharmaceutical Association's annual meeting in Coral Gables, Fla., April 10. "This is not to say that DPK is completely off the radar screen - we will continue to look at it - but we felt like we wanted to get the guidance out of publication." The agency has been considering alternatives following an unfavorable advisory committee meeting (1"The Pink Sheet" Dec. 17, 2001, p. 40)...
You may also be interested in...
Topical dermatological drug product bioequivalence methods may vary according to product classes, FDA Division of Dermatologic & Dental Drug Products Director Jonathan Wilkin, MD, told the Pharmaceutical Science Advisory Committee March 12
Studies of bioequivalence methods by FDA's Office of Generic Drugs will be directed by its Research Initiatives Committee
FDA is considering evaluating alternatives to dermatopharmacokinetics for determining bioequivalence of topical dermatological products